Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants
Circulation · 14.10.2025 · 152 (15) · 1060-1075
DOI: 10.1161/circulationaha.125.074529 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 14.10.2025. Verfasst von Soledad García Hernandez und 28 weiteren Autor:innen. Beteiligte Einrichtung: Health in Code S.L, A Coruña, Spain (S.G.H.). Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Genetic Variation. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol Myers Squibb Foundation.
Abstract (Originalsprache)
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disorder linked primarily to rare variants in sarcomeric genes, although recently certain nonsarcomeric genes have emerged as important contributors. Nonmendelian genetic variants with reproducible moderate-effect sizes and low penetrance, intermediate-effect variants (IEVs), can play a crucial role in modulating disease expression. Understanding the clinical impact of IEVs is crucial to unravel the complex genetic architecture of HCM. METHODS: We conducted an ancestry-based enrichment analysis of 14 validated HCM genes, including the 9 core sarcomeric and 5 nonsarcomeric genes (ALPK3 , CSRP3 , FHOD3 , FLNC , and TRIM63 ). Enrichment of intermediate frequency missense variants was evaluated in 10 981 patients with HCM, 4030 internal controls of European-ancestry, and 590 000 external controls from gnomAD non-Finnish Europeans. The population-attributable fraction was calculated to assess contribution of IEVs to HCM. Age-related disease penetrance, phenotypic severity (left ventricular maximum wall thickness), and major adverse cardiac events were analyzed in 11 991 HCM cases of the whole cohort according to 5 genetic groups: genotype negative, isolated IEV, monogenic, monogenic+IEV, and double monogenic. RESULTS: Fourteen IEVs in 8 genes were identified in 731 individuals (6.1% of the cohort), of whom 570 patients (4.8%) had IEVs in isolation: 198 (34.7%) in sarcomeric genes and 372 (65.3%) in nonsarcomeric genes. The contribution of IEVs to HCM genetics according to population-attributable fraction was estimated to be 4.9% (95% CI, 3.2–6.7). A significant gradient in penetrance, phenotypic severity, and major adverse cardiac events was observed across genetic groups. Compared with genotype-negative patients, IEV carriers displayed a younger median age at diagnosis (59 years of age [95% CI, 46–69] versus 61 years [95% CI, 49–70]; P =0.0073) and a higher mean left ventricular maximum wall thickness (18.1±3.7 versus 19.0±4.3; P =0.0043). IEVs also modified disease expression in individuals with monogenic variants, causing a more aggressive phenotype than in individuals from the monogenic-only group with HCM onset at younger age and a higher left ventricular maximum wall thickness (all P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health in Code S.L, A Coruña, Spain (S.G.H.).
- Universidade da Coruña, Spain. Inherited Cardiac Diseases Unit, San Cecilio Hospital. Granada, Spain (S.G.H.).
- Health in Code S.L, A Coruña, Spain (L.d.l.H.R.).
- Favaloro Foundation University Hospital, Cardiology, Buenos Aires, Argentina (A.F.).
- Department of Cardiology, Hospital Universitario Virgen del Rocío, Sevilla, Spain (M.L.P.P.).
- Department of Cardiology, Hospital, Universitario Puerta de Hierro, IDIPHISA, CIBERCV, Madrid, Spain (N.M.-A).
ORCID-Profile: Soledad García Hernandez, Adrian Fernandez, Maria Luisa Peña Peña, Nerea Mora-Ayestaran, María Teresa Basurte-Elorz, Jose María Larrañaga-Moreira, Eduardo Villacorta, Maria Valverde-Gómez, Alex Lipov, Eduardo Moreno-Escobar, Petros Syrris, Xusto Fernández, Jesús Piqueras-Flores, Connie R Bezzina, Perry M Elliott, Roberto Barriales-Villa, Juan Ramon Gimeno-Blanes, Pablo García-Pavía, Roddy Walsh, Juan Pablo Ochoa
Förderung
- Bristol Myers Squibb Foundation
Zitieren
APA
García Hernandez, S., de la Higuera Romero, L., Fernandez, A., Luisa Peña Peña, M., Mora-Ayestaran, N., Basurte-Elorz, M. T., Larrañaga-Moreira, J. M., Cárdenas Reyes, I., Villacorta, E., Valverde-Gómez, M., Baustista-Paves, A., Veira Villanueva, E., Ortiz-Genga, M., Lipov, A., Brogger, N., Sabater Molina, M., Moreno-Escobar, E., Ruiz-Guerrero, L., Syrris, P., …, & Ochoa, J. P. (2025). Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants. Circulation, 152(15), 1060-1075. https://doi.org/10.1161/circulationaha.125.074529
Vancouver
García Hernandez S, de la Higuera Romero L, Fernandez A, Luisa Peña Peña M, Mora-Ayestaran N, Basurte-Elorz MT, et al. Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants. Circulation. 2025;152(15):1060-1075. doi:10.1161/circulationaha.125.074529
BibTeX
@article{GarcaHernandez2025,
author = {García Hernandez, Soledad and de la Higuera Romero, Luis and Fernandez, Adrian and Luisa Peña Peña, Maria and Mora-Ayestaran, Nerea and Basurte-Elorz, María Teresa and Larrañaga-Moreira, Jose María and Cárdenas Reyes, Ivonne and Villacorta, Eduardo and Valverde-Gómez, Maria and Baustista-Paves, Alicia and Veira Villanueva, Elena and Ortiz-Genga, Martín and Lipov, Alex and Brogger, Noel and Sabater Molina, María and Moreno-Escobar, Eduardo and Ruiz-Guerrero, Luis and Syrris, Petros and Fernández, Xusto and Piqueras-Flores, Jesús and Amor Salamanca, Almudena and Bezzina, Connie R and Elliott, Perry M and Barriales-Villa, Roberto and Gimeno-Blanes, Juan Ramon and García-Pavía, Pablo and Walsh, Roddy and Ochoa, Juan Pablo},
title = {Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants},
journal = {Circulation},
year = {2025},
volume = {152},
number = {15},
pages = {1060--1075},
doi = {10.1161/circulationaha.125.074529}
}
EUVIMED